Maynard Howe, vice chairman and CEO of Stemedica, said: “Stemedica is executing a dual-path strategy in which the Stemedica USA facility will continue to manufacture current good manufacturing practices (cGMP) clinical grade stem cells as it works to gain the FDA’s investigational new drug approval to begin clinical trials.
“Stemedica International will manufacture cGMP clinical grade stem cells to meet the ever-growing demand for clinical trials in Switzerland and other countries.”
Roger Howe, executive chairman of Stemedica USA, said: “We’re also extremely fortunate to have secured Frank Schuller as chairman of Stemedica International. Along with his business acumen and international reputation, Frank brings a depth and breath of experience as well as governmental and financial networks critical to our global expansion.”